Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Compare the Bioavailability of Extended Release Metformin HCl Tablet Versus Glucophage XR® Tablets in Healthy Human Volunteers Under Fasting Condition

This study has been completed.
Sponsor:
Information provided by:
Torrent Pharmaceuticals Limited
ClinicalTrials.gov Identifier:
NCT01089166
First received: March 16, 2010
Last updated: June 18, 2010
Last verified: March 2010
  Purpose

Objective: To compare the bioavailability of Extended Release Metformin HCl Tablet(Test formulation, Torrent Pharmaceuticals Ltd.,India) versus Glucophage XR® Tablets ( Reference formulation, Bristol-Myers Squibb Company, USA) in Healthy Human Volunteers under fasting condition.

Study Design: An Open-Label, Randomised, 2-Period, 2-Treatment,Crossover Study under fasting condition.


Condition Intervention Phase
Type 2 Diabetes
Drug: Metformin
Phase 1

Study Type: Interventional
Official Title: To Compare the Bioavailability of Extended Release Metformin HCl Tablet(Test Formulation, Torrent Pharmaceuticals Ltd.,India) Versus Glucophage XR® Tablets ( Reference Formulation, Bristol-Myers Squibb Company, USA) in Healthy Human Volunteers Under Fasting Condition

Resource links provided by NLM:


Further study details as provided by Torrent Pharmaceuticals Limited:

Arms Assigned Interventions
Experimental: Torrent's Metformin tablets 500 mg Drug: Metformin
Active Comparator: Glucophage XR® of Bristol- Myers Squibb Company, USA) Drug: Metformin

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Criteria

Inclusion Criteria:

  • Subjects must meet all of the following criteria in order to be included in the study:

    1. Sex: male.
    2. Age: 18 - 45 years.
    3. Subject with BMI of 18-27 (inclusive both) kg/m2 with minimum of 50 kg weight.
    4. Healthy and willing to participate in the study.
    5. Subject willing to adhere to the protocol requirements and to provide written informed consent.
    6. Non-smokers or smoker who smokes less than 10 cigarettes a day.

Exclusion Criteria:

  • The subjects will be excluded from the study based on the following criteria:

    1. Clinically relevant abnormalities in the results of the laboratory screening evaluation.
    2. Clinically significant abnormal ECG or Chest X-ray.
    3. Systolic blood pressure less than 100 mm Hg or more than 140 mm Hg and diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.
    4. Pulse rate less than 50/minute or more than 100/minute.
    5. Oral temperature less than 95°F or more than 98.6°F.
    6. Respiratory rate less than 12/minute or more than 20/minute
    7. Addiction to alcohol or history of any drug abuse within the past 2 years.
    8. Recent History of kidney or liver dysfunction.
    9. History of allergy to the test drug or any drug chemically similar to the drug under investigation.
    10. Administration/ Intake of prescription or OTC medication for two weeks before the study.
    11. Patients suffering from any chronic illness such as arthritis, asthma etc.
    12. HIV, HCV, HBsAg positive Subjects.
    13. Opioids, tetra hydrocannabinoids, amphetamine, barbiturates, benzodiazepine, Cocaine positive Subjects based on urine test.
    14. Subjects suffering from any psychiatric (acute or chronic) illness requiring medications.
    15. Administration of any investigational products in the period 0 to 3 months before entry to the study.
    16. Intake of barbiturates or any enzyme-inducing drug in last three months.
    17. History of significant blood loss due to any reason, including blood donation in the past 12 weeks. The total blood loss in last 3 months including for this study will not exceed 350ml.
    18. History of any bleeding disorder.
    19. Existence of any surgical or medical condition, which, in the judgement of the Chief investigator and/or clinical investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug or likely to compromise the safety of Subjects.
    20. Inability to communicate or co-operate due to language problem, poor mental development or impaired cerebral function.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01089166

Locations
India
Torrent Research Centre
Bhat, Gujarat, India, 382 428
Sponsors and Collaborators
Torrent Pharmaceuticals Limited
Investigators
Principal Investigator: Jogesh mahajan, MBBS Torrent Pharma Ltd.
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT01089166     History of Changes
Other Study ID Numbers: PK-07- 016
Study First Received: March 16, 2010
Last Updated: June 18, 2010
Health Authority: India: Drugs Controller General of India
United States: Institutional Review Board

Additional relevant MeSH terms:
Diabetes Mellitus, Type 2
Diabetes Mellitus
Endocrine System Diseases
Glucose Metabolism Disorders
Metabolic Diseases
Metformin
Hypoglycemic Agents
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on November 20, 2014